# US 2009/0270504 A1 · Treatment of Huntington's Disease With EPA

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0270504 A1
- Document ID: US20090270504A1
- Status: Published application
- Kind: A1
- Application number: 12/429,825
- Filed: 2009-04-24
- Published: 2009-10-29
- Earliest claimed: 2002-12-02
- Assignees: Amarin Neuroscience Limited
- Inventors: David Frederick Horrobin; Sherri Clarkson
- Web page: https://patentgrep.com/patent/US20090270504A1

## CPC

- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Analysis of the huntington gene provides a method for identifying patients likely to respond to treatment of Huntington's disease with eicosapentaenoic acid, EPA.

## Claims

### Claim 1

A method of identifying patients with Huntington's disease, or individuals who are at risk of developing Huntington's disease, who will respond to treatment with eicosapentaenoic acid (EPA) in any bioavailable form comprising the step of determining the number of CAG repeats in the Huntingtin gene and identifying those subjects with 45 or fewer repeats.

### Claim 2 (depends on 1)

The method of claim 1, in which the treatment comprises administration of eicosapentaenoic acid (ethyl-EPA).

### Claim 3

A method of treating Huntington's disease comprising the steps of identifying patients having 45 or fewer CAG repeats in the gene for huntingtin and administering to those patients eicosapentaenoic acid (EPA) in any bioavailable form.

### Claim 4

A method of preventing the development of symptoms in individuals who are at risk of developing Huntington's disease comprising the steps of identifying individuals having 45 or fewer CAG repeats in the gene for huntingtin and administering to those individuals eicosapentaenoic acid (EPA) in any bioavailable form.

### Claim 5 (depends on 3)

The method of claim 3 in which the eicosapentaenoic acid (EPA) administered is in the form of ethyl-eicosapentaenoic acid (ethyl-EPA).

### Claim 6 (depends on 4)

The method of claim 4 in which the eicosapentaenoic acid (EPA) administered is in the form of ethyl-eicosapentaenoic acid (ethyl-EPA).
